Match the
tumor
to its therapy
Comprehensive somatic tumor profiling on the OncoMine platform — coverage of the actionable cancer gene landscape with biomarkers (MSI, TMB, PD-L1) for immunotherapy eligibility. Built for FFPE specimens.
Different question, different test
A germline cancer panel asks “what risk did I inherit?” Somatic tumor profiling asks “what is driving this tumor right now, and which targeted or immune therapy fits?” Both have a place — but they answer different clinical questions.
Treatment selection
Identify FDA-approved targeted therapies and trial-eligible alterations for the patient in front of you.
Immunotherapy biomarkers
MSI, TMB, and PD-L1 (when paired with IHC) are reported together to inform checkpoint-inhibitor eligibility.
FFPE-ready
Optimized for archived FFPE blocks, validated to operate at low tumor content with strong analytical sensitivity.
Genomic signal, in one report
Variants and biomarkers are co-reported with tier classification (AMP/ASCO/CAP) and database annotation (OncoKB, ClinVar).
Hotspot mutations
Activating and loss-of-function variants across the actionable cancer gene set.
Copy number alterations
Amplifications and deletions called from sequencing depth.
Gene fusions
RNA-based detection of clinically relevant fusion partners.
Microsatellite instability
Reported as MSI-High or MSS using sequence-based scoring.
Tumor mutational burden
Mutations per megabase, calibrated against reference material.
PD-L1 (paired)
Reported alongside referring-center IHC when provided.
Homologous recombination
HRD-related variants flagged for PARP-inhibitor eligibility review.
Specimen QC
DNA quality, tumor content, and minimum coverage thresholds reported.
Sample report excerpt
A redacted view of the variants and biomarker section. Tier classification follows AMP/ASCO/CAP guidelines; therapeutic relevance is annotated through OncoKB.
| Gene / variant | HGVS | VAF | Tier | Therapeutic relevance |
|---|---|---|---|---|
| EGFR L858R Exon 21 missense, activating | NM_005228.5:c.2573T>G | 38.4% | TIER I | FDA-approved EGFR TKIs (osimertinib first line in NSCLC). Sensitizing mutation. |
| TP53 R175H DNA-binding domain hotspot | NM_000546.6:c.524G>A | 41.2% | TIER II | Prognostic. Co-occurring with EGFR drivers in NSCLC. Clinical trial eligibility may apply. |
| CDKN2A deletion Homozygous loss, exons 1–3 | CNV: 0.05 (homozygous) | — | TIER II | CDK4/6 inhibitor sensitivity in select tumor types. Trial eligibility. |
| MET amplification Focal high-level CN gain · 7q31.2 | CNV: 8.4 copies | — | TIER II | Capmatinib / tepotinib activity in MET-amplified NSCLC. Trial eligibility (NCT04606771). |
| KRAS WT Codons 12, 13, 61, 117, 146 negative | — | < 1% | REF | Wild-type. Confirms EGFR-driven biology; consistent with EGFR TKI candidacy. |
| PIK3CA E545K Helical domain hotspot | NM_006218.4:c.1633G>A | 11.8% | TIER III | Variant of uncertain clinical significance in this tumor type. No established targeted therapy. |
| STK11 Q37* Truncating, exon 1 | NM_000455.5:c.109C>T | 33.7% | TIER III | Resistance signal: associated with reduced ICI benefit in NSCLC. Co-occurring with KEAP1 to be ruled out. |
| EML4–ALK fusion Not detected · RNA fusion panel | — | — | REF | Not detected. ROS1, RET, NTRK1/2/3 also negative. |
From variant to clinical decision
Each Tier I and Tier II finding is paired with FDA-approved targeted therapies, NCCN-listed regimens, and active clinical-trial options drawn from a curated knowledge base.
Speak with the oncology team
Submit a tumor block, request a sample report, or talk through assay selection between the Standard, Comprehensive, and Liquid Biopsy options.